Overactive bladder is a chronic condition that affects 10–45% of women worldwide;1 however, more than half of women discontinue conservative and medical treatment.2,3 Predicting which women are better ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

Women with ongoing urinary incontinence could avoid invasive bladder pressure tests, as new research shows that a range of ...

Dizal announces new findings on golidocitinib; to present clinical results at ELCC 2025 in Paris on March 26-29: Shanghai Saturday, March 22, 2025, 17:00 Hrs [IST] Dizal, a biopha ...

Wojciech Jurczak, MD, PhD, ​​discusses nemtabrutinib and its development for the treatment of follicular lymphoma.

In order to fulfill these requirements many industry branches in- and outside Europe currently undergo enormous ...

Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for TAZVERIK® (tazemetostat) has been granted conditional approval in China for the treatment of ...

China’s National Medical Products Administration (NMPA) has granted conditional approval for Hutchmed’s Tazverik ...

Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen ...

Fintel reports that on March 21, 2025, Cantor Fitzgerald initiated coverage of GlycoMimetics (NasdaqCM:GLYC) with a ...

Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio Inc. for $600 million upfront ...

The New Drug Application (NDA) for Tazverik (tazemetostat) has been granted conditional approval in China for the treatment ...